Response of mTOR inhibitor associated with mutation of FBXW7 gene identified by comprehensive genomic profiling in cervical squamous cell carcinoma supports additional therapy opportunity for select patients with treatment-refractory, recurrent disease

Abstract

Objective: More than 90% of patients with recurrent cervical squamous cell carcinoma (cSCC) die within 5 years. We describe 2 cases of prolonged clinical response of advanced recurrent cSCC to mTOR inhibitor (mTORi) monotherapy after genomic tumor testing indicated susceptibility. The FoundationOne tumor genomic database was queried to identify the frequency of such mutations in advanced cSCC.